Overview
1. Introducción
Este mes son prominentes los autos de homologación de planes de restructuración (en su mayoría no consensuales) que seguimos viendo. En ese mismo campo destacamos la desestimación de la impugnación del ya famoso plan de Torrejón Salud (plan con una única clase) que se ha instaurado como un "leading case" en la práctica. Los recurrentes son condenados en costas.
Todo esto y más resúmenes de resoluciones que nos han parecido interesantes a continuación.
2. Audiencias Provinciales
Background
The Times revealed in an article last month that, according to a report from the Audit Reform Lab, a think tank at the University of Sheffield, only a quarter of the 250 largest companies listed on the London Stock Exchange to become insolvent between 2010 and 2022 had a “going concern” warning included by their auditors in what would turn out to be their final set of accounts. Of those companies 38 also declared a dividend in those accounts.
On 1 July 2024, the Employment (Collective Redundancies and Miscellaneous Provisions) and Companies (Amendment) Act 2024 was commenced in full and is now law.
Releases of Sackler Family Too Broad and Not Authorized by the Bankruptcy Code
SUMMARY
Last week, in a 5-to-4 decision in the case ofHarrington, United States Trustee, Region 2 v. Purdue Pharma L.P, et al., the U.S. Supreme Court struck down the ability of bankruptcy courts to order non-consensual third-party releases (i.e., claims held by non-debtors against non-debtor third parties) as part of a Chapter 11 plan.
The High Court has handed down a 533-page judgment in proceedings brought by the liquidators of BHS against its former directors for wrongful trading and misfeasance trading, finding them personally liable for at least £18 million. The case is of great significance to directors of distressed companies. We analyse some key points arising.
Click here to view the judgment.
Background
This article analyses the extent to which dissenting financial creditors are protected under the Indian insolvency regime.
Here’s a dilemma:
- Should bankruptcy be available as a tool for resolving mass tort cases of all types (like it already is in asbestos contexts)?
Here’s an illustration of the dilemma:
- many tort claimants in the Johnson & Johnson case DO NOT want bankruptcy involved; but
- many tort claimants in the Purdue Pharma case were BEGGING the courts to approve the bankruptcy plan.
How do we solve this dilemma?
BACKGROUND
Since its inception the Insolvency and Bankruptcy Code, 2016 (Code) has been an evolving legislation with regular updation(s) being brought about in the form of rules and regulations with a view of streamlining the corporate insolvency resolution process (CIRP).